Novartis India Ltd Stock Price Today (NSE: NOVARTIND)
Fundamental Score
Novartis India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Novartis India Ltd share price today is ₹672.25, up +0.00% on NSE/BSE as of 30 March 2026. Novartis India Ltd (NOVARTIND) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.00K (Cr). The 52-week high for NOVARTIND share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 18.79x, NOVARTIND is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.18% and a debt-to-equity ratio of 0.01.
Novartis India Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Novartis India Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Novartis Share Price: A Financial Stability Analysis
The pharmaceutical industry, a sector inherently characterized by heavy R&D investments and lengthy regulatory approval processes, demands rigorous financial analysis. This report examines the financial stability of Novartis India Ltd, focusing on key metrics and peer comparisons. The current Novartis share price stands at ₹810.95. This analysis forms part of a comprehensive, 80-parameter fundamental audit, verified by Sweta Mishra, and aims to provide an observational perspective on the company's financial health. No investment recommendations are made.
Novartis India Ltd reports a Price-to-Earnings (PE) ratio of 18.79. While PE ratios can offer insight on relative valuation, they should be evaluated contextually. When compared to sector peers like
Mankind Pharma Ltd, which may exhibit different growth rates and risk profiles, the PE ratio offers a starting point for comparative analysis. For example, assessments of management quality can play a large part in deciding which company may make better decisions. A deeper investigation into the operational efficiencies and strategic decisions of both Novartis and Mankind Pharma would be needed to determine which company has better management.A crucial indicator of financial stability is the company's Return on Capital Employed (ROCE), which stands at 17.0% for Novartis India Ltd. ROCE measures how effectively a company is using its capital to generate profits. A higher ROCE generally suggests a stronger competitive advantage and more efficient capital allocation. In Novartis's case, a 17.0% ROCE contributes significantly to building and maintaining its economic moat, signifying the company's ability to generate sustainable profits and defend its market position. Companies such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd operate under a different set of risk and growth potential than Novartis India Ltd and are useful to compare.
In conclusion, evaluating the Novartis share price requires a holistic view encompassing its PE ratio, ROCE, and comparison with sector peers. The 17.0% ROCE appears to contribute positively to the company's financial stability. Further investigation into operational efficiencies, management strategies, and broader industry dynamics is recommended to develop a more complete understanding of the company's long-term financial prospects. This analysis is purely observational and based on publicly available information at the time of writing.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Novartis India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NOVARTIND across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (17.00%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 18.79 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (58.46% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (58.46% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (202.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹202.03 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (70.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Attractive Dividend Yield (3.08%)
Observation: Healthy dividend yield provides income component to returns.
Analysis: Dividend yield >3% offers income potential while indicating cash flow strength.
Risk Factors
2 factors identified
Limited Growth History (-4.06% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.72%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Novartis India Ltd Financial Statements
Comprehensive financial data for Novartis India Ltd including income statement, balance sheet and cash flow
About NOVARTIND (Novartis India Ltd)
Novartis India Ltd is a prominent player in the Indian pharmaceutical landscape, dedicated to advancing healthcare solutions across a spectrum of therapeutic areas. With a strong c...ommitment to innovation and patient well-being, the company develops, manufactures, and markets a diverse portfolio of pharmaceutical products. These offerings address critical medical needs, contributing to improved health outcomes and enhanced quality of life for patients throughout India. Novartis India's unwavering focus on research and development ensures a continuous pipeline of innovative therapies, solidifying its position as a leader in the Indian pharmaceutical industry. The company's product range encompasses vital medications in diverse areas, most notably in bone and pain management with the well-established Voveran brand. Further extending its reach, Novartis India provides essential therapies in transplantation immunology, offering hope and improved outcomes for patients undergoing organ transplantation through brands like Simulect, Certican, Sandimmun, Neoral, and Myfortic. In the field of neuroscience, Novartis India contributes significantly by providing treatments for neurological disorders, with established brands such as Tegrital and Exelon, improving the lives of patients facing neurological challenges. Headquartered in the bustling city of Mumbai, India, Novartis India has a rich heritage dating back to its incorporation in 1947. As a subsidiary of the globally renowned Novartis AG, it leverages the parent company's extensive resources, cutting-edge research, and global network to deliver high-quality pharmaceutical products and services to the Indian market. Novartis India's presence is a testament to its enduring commitment to addressing the evolving healthcare needs of the nation, contributing to the overall health and well-being of the Indian population.
Company Details
Key Leadership
NOVARTIND Share Price: Frequently Asked Questions
What is the current share price of Novartis India Ltd (NOVARTIND)?
As of 30 Mar 2026, 11:00 am IST, Novartis India Ltd share price is ₹672.25. The NOVARTIND stock has a market capitalisation of ₹2.00K (Cr) on NSE/BSE.
Is NOVARTIND share price Overvalued or Undervalued?
NOVARTIND share price is currently trading at a P/E ratio of 18.79x, compared to the industry average of 31.77x. Based on this relative valuation, the Novartis India Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of NOVARTIND share price?
The 52-week high of NOVARTIND share price is ₹N/A and the 52-week low is ₹N/A. These values are updated daily from NSE/BSE price data.
What factors affect the Novartis India Ltd share price?
Key factors influencing NOVARTIND share price include quarterly earnings growth (Sales Growth: 3.71%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Novartis India Ltd a good stock for long-term investment?
Novartis India Ltd shows a 5-year Profit Growth of 58.46% and an ROE of 13.18%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing in NOVARTIND shares.
How does Novartis India Ltd compare with its industry peers?
Novartis India Ltd competes with major peers in the Pharmaceuticals. Investors should compare NOVARTIND share price P/E of 18.79x and ROE of 13.18% against the industry averages to determine competitive standing.
What is the P/E ratio of NOVARTIND and what does it mean?
NOVARTIND share price has a P/E ratio of 18.79x compared to the industry average of 31.77x. Investors pay ₹19 for every ₹1 of annual earnings.
How is NOVARTIND performing according to Bull Run's analysis?
NOVARTIND has a Bull Run fundamental score of 61.8/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NOVARTIND belong to?
NOVARTIND operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Novartis India Ltd share price.
What is Return on Equity (ROE) and why is it important for NOVARTIND?
NOVARTIND has an ROE of 13.18%, which shows decent profitability but room for improvement. ROE measures how efficiently Novartis India Ltd generates profits from shareholders capital.
How is NOVARTIND debt-to-equity ratio and what does it indicate?
NOVARTIND has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk.
What is NOVARTIND dividend yield and is it a good dividend stock?
NOVARTIND offers a dividend yield of 3.08%, meaning you receive ₹3.08 annual dividend for every ₹100 invested in Novartis India Ltd shares.
How has NOVARTIND share price grown over the past 5 years?
NOVARTIND has achieved 5-year growth rates of: Sales Growth -4.06%, Profit Growth 58.46%, and EPS Growth 58.46%.
What is the promoter holding in NOVARTIND and why does it matter?
Promoters hold 70.68% of NOVARTIND shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Novartis India Ltd.
What is NOVARTIND market capitalisation category?
NOVARTIND has a market capitalisation of ₹2002 crores, placing it in the Small-cap category.
How volatile is NOVARTIND stock?
NOVARTIND has a beta of N/A. A beta > 1 suggests the Novartis India Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NOVARTIND operating profit margin trend?
NOVARTIND has a 5-year average Operating Profit Margin (OPM) of 14.90%, indicating the company's operational efficiency.
How is NOVARTIND quarterly performance?
Recent quarterly performance shows Novartis India Ltd YoY Sales Growth of 3.71% and YoY Profit Growth of 18.67%.
What is the institutional holding pattern in NOVARTIND?
NOVARTIND has FII holding of 0.19% and DII holding of 0.53%. Significant institutional holding often suggests professional confidence in the Novartis India Ltd stock.